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Abstract 
 
Background: Chinese herbal decoction (CHD) has been extensively used in the treatment of atrophic gastritis (AG) in 
China and other Far Eastern countries. We conducted a systematic review and meta-analysis to estimate the efficacy 
and safety of CHD in AG. 
Materials and Methods: Pubmed, Embase, Cochrane central register of controlled trials (central), VIP, China National 
Knowledge Infrastructure, Sinomed, Wanfang data were searched (up to December 2015). Randomized controlled trials 
recruiting patients with AG comparing CHD (alone or with western medicine (WM)) with WM were eligible. 
Dichotomous data were pooled to obtain relative risk (RR), with a 95% confidence interval (CI). 
Results: Forty-two articles including 3,874 patients were identified. CHD, used alone or with WM, had beneficial 
effect over WM in the improvement of clinical manifestations (RR=1.28; 95% CI 1.22-1.34) and pathological change 
(RR=1.42; 95% CI 1.30-1.54) for AG patients. However, the H. pylori eradication effect of CHD was not supported by 
the existing clinical evidence, because of the significant study heterogeneity (I2>50%) and inconsistency between the 
primary results and sensitivity analysis. 
Conclusions: CHD, if prescribed as a complementary therapy to WM, may improve the clinical manifestations and 
pathological change for AG patients. But its monotherapy for H. pylori eradication is not supported by enough clinical 
evidence. 
 
Key words: atrophic gastritis; Helicobacter pylori; Chinese herbal decoction; meta-analysis 
 
Abbreviations: AG, atrophic gastritis; TCM, traditional Chinese medicine; CHD, Chinese herbal decoction; WM, 
western medicine; Int. CHD-WM, integration of Chinese herbal decoction and western medicine; RCTs, randomized 
controlled trials; RR, relative risk; CI, confidence interval; I2, inconsistency index 
  
Introduction 
 
Atrophic gastritis (AG) is defined as the non-metaplastic and metaplastic atrophy of gastric mucosa which is 
replaced by connective tissue or glandular structures inappropriate for location, such as intestinal-type epithelium and 
pyloric-type glands (Rugge et al., 2011). Epidemiological surveys revealed that the global incidence of AG is about 
0-10.9% (Adamu et al., 2010), and the prevalences are higher in Far Eastern countries (such as China, Japan, and Korea) 
than those in the western ones (Aoki et al., 2005; Weck and Brenner,2006; Weck et al., 2007). The persistent H. 
pylori-related inflammatory condition is one of the most important pathogeneses of AG (Eid and Moss, 2002), making 
the risk for intestinal-type gastric cancer 5.13 to 24.71-fold higher in gastritis patients than in normal people (Kato et al., 
1992). H. pylori eradication therapies, such as the one-week combined use of moxifloxacin, tetracycline and 
lansoprazole, are recommended by the western medicine (WM) system to control AG (Taş et al., 2011). However, some 
recent studies reported that the clinical eradication rate of H. pylori has decreased to an unacceptable low level of 
25%-80% (Gisbert et al., 2007; Graham and Fischbach,2010; Gumurdulu et al., 2004). The main causes of eradication 
failure are the poor compliance of patients, emerging resistant H. pylori strains and adverse drug reactions (Graham and 
Fischbach, 2010; Megraud, 2004; Safavi et al., 2015). The unsatisfactory efficacy and safety in WM emphasize the 
need for more alternative approaches to the managing AG. 
Traditional Chinese Medicine (TCM) has been widely used for treating gastritis in China and other Far Eastern 
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countries for tens of centuries (Chen et al., 2003; Qin et al., 2013; Tang et al., 2016; Xia,2004). Nowadays, Chinese 
physicians often prescribe TCM combined with WM, in the belief that patients will benefit from both the western and 
Chinese traditional therapies (Lu and Chen, 2015). Among the widely-used herbal decoctions, tens of herbs (e.g. Abrus 
cantoniensis Hance, Saussurea lappa (Decne.) Sch.Bip, Eugenia caryophyllata Thunb) showed potent anti-H. pylori 
activity (MICs: ∼40μg/ml) (Li et al., 2005; Safavi et al., 2015). Certain herbal extracts were also proved to effectively 
exhibit anti-inflammatory activity and reduce gastric symptoms by suppressing the production of nitric oxide, 
prostaglandin E(2), cyclooxygenase-2, TNF-α, IL-6 and interleukin 1β (Meng and Yang, 2010; Song et al., 2009). 
Clinical trials showed that some Chinese decoctions or herbal extracts were effective in alleviating AG symptoms and 
eradicating H. pylori (Meng and Yang,2010; Song et al., 2009), without increasing the incidence of adverse effects or 
producing resistant colonies (Higuchi et al., 1999). Although TCM may be a promising supplement to WM, there is no 
evidence from large-scale, multicenter clinical trials on its clinical use. Hence, we performed a systematic review and 
meta-analysis to evaluate the efficacy and safety of Chinese herbal decoction (CHD), the most essential and traditional 
part of TCM, for AG treatment. 
 
Material and methods 
Search strategy and study selection 
 
A comprehensive retrieval was conducted in seven electronic databases of PubMed (1966 to December 2015), 
Embase (1980 to December 2015), Cochrane central register of controlled trials (central) (Issue 7, 2015), Sinomed (up 
to 2015), VIP Information (up to 2015), China National Knowledge Infrastructure (up to 2015) and Wangfang Data (up 
to 2015), without language restriction. AG of H. pylori origin, rather than autoimmune origin, was included in this 
study. Only randomized controlled trials (RCTs) were eligible for inclusion in this review. Trials should compare CHD 
(used alone or plus WM) versus WM. In WM group, patients with gastrointestinal symptoms (gastrectasia, 
stomach-ache, dyspepsia, etc.) should be alleviated by medications such as proton pump inhibitor; and patients with H. 
pylori should be treated with eradication therapy, such as triple therapy. AG should be diagnosed according to case 
history and pathological diagnosis (atrophy of the gastric mucosa, intestinal metaplasia, atypical hyperplasia, 
inflammatory cell infiltration, exposed sub-mucosal vessels). Diagnosis of H. pylori should be based invasively on 
endoscopic biopsy check with a rapid urease test, histological examination, or microbial culture; or noninvasively on a 
blood antibody test, stool antigen test, or carbon urea breath test. Efficacy is assessed by improvement of clinical 
manifestations (alleviation of gastrectasia, stomach-ache, dyspepsia, etc.), pathological diagnosis (alleviation of atrophy 
of the gastric mucosa, intestinal metaplasia, atypical hyperplasia, inflammatory cell infiltration, and exposed 
submucosal vessels), and the eradication of H. pylori. The authors of related studies were contacted to provide 
additional information on trials where required. Search terms used in this study were traditional Chinese medicine, 
herbal medicine, atrophic gastritis, randomized controlled trial, phytotherapy (both as medical subject heading (MeSH) 
and free text terms), or the following free text terms: herbal, Chinese medicine, traditional medicine, and the names of 
widely used formulae, such as Ban-Xia-Xie-Xin decoction, Wei-Su-Chong-Ji decoction, Xiao-Jian-Zhong decoction, 
Hou-Bu-Wen-Zhong decoction, etc. We also searched the reference lists of the original reports, reviews, and letters to 
the editor, case reports and meta-analyses of studies to identify studies which had not yet been included in the 
computerized databases. The last search was performed on 1st December 2015. Two reviewers (WJF, XYZ) 
independently assessed the eligibility of each study to be included in our meta-analysis using predesigned eligibility 
forms according to eligible criteria, and this was checked by another author (BY). Any disagreement was resolved by 
consensus between the two reviewers (SJS, ZM), adjudicated with the support of a third reviewer (BY). 
 
Data collection process and data items  
 
Data extraction were performed by three reviewers (WJF, XYZ, BY) with a Microsoft Excel spreadsheet (XP 
professional edition; Microsoft, Redmond, Washington, USA), and any disagreement was resolved by discussion. We 
consulted authors of the original studies through emails to get information if any problem occurred. The following data 
were collected: study design, sample size, therapeutic duration, criteria for efficacy judgment, intervention and control, 
eradication rate of H. pylori, clinical manifestation improvement, pathological improvement, adverse events. 
 
Assessment of risk of bias  
 
The studies were appraised independently by two authors (WJF, XYZ). Considering the different features of CHD 
from WM, we appropriately modified the Jadad scale, as some previous meta-analyses did. (Xu. et al.,2011; Zou et al,. 
2011) The modified Jadad scale was as follows: (1) was the study described as randomized? (2-properly with detailed 
description of randomization, 1-randomized but detail not reported, 0-inappropriate randomization); (2) was allocation 
concealment used? (2-properly used, 1-unclear, 0-not used); (3) was the blind method used? (2-double-blind, 
1-single-blind, 0-open-label); (4) were dropout and follow-up reported? (1-numbers and reasons reported, 0-not 
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reported); and (5) was the treatment based on TCM symptom types (also called Bianzheng Lunzhi in Chinese 
(Karchmer,2013))? (2-properly with detailed description, 1-mentioned but detail not reported, 0-not mentioned or 
inappropriate). A study with a quality score ≤2 was considered as a study at high risk of bias, a study with a quality 
score ≥ 5 was considered as a study at low risk of bias, and the left were at moderate risk of bias. 
 
Summary measures and synthesis of results 
 
We undertook separate synthesis for each comparison. Dichotomous data were summarized as relative risk (RR) 
with 95% Confident Intervals (CIs), and a random effects model (DerSimonian and Laird,1986) was used whether 
heterogeneity was found in order to gain a more conservative outcome. When the authors reported dichotomous data 
(effective or ineffective), we retrieved them directly. In studies where multiple strata were given to define improvement, 
we converted these outcomes into dichotomous data to permit the overall analysis. Since the included study use the 
same validated criteria for the judgement of cure, we grouped together cure, significant improvement, and improvement 
as effective and no improvement, deterioration, as ineffective. Publication bias was examined using funnel plot and 
Egger’s tests. Heterogeneity between studies was tested using the inconsistency index (I2) statistic with a cutoff of 50%. 
The statistical analysis was carried out with RevMan 5.0 software (Copenhagen, The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2008) and Stata/SE version 10.0 (StataCorp, College Station, Texas, USA). 
 
Sensitivity analysis 
 
Because the poor-quality of RCT design might lead to exaggerated estimates of intervention benefit (Kjaergard et 
al.,2001), sensitivity analyses were performed to evaluate the robustness of outcomes and identify sources of 
heterogeneity. We conducted predesigned sensitivity analyses among studies of low to moderate risk of bias (modified 
Jadad score ≤2). 
 
Results 
Study characteristics and risk of bias 
 
The search strategy was shown in the flow diagram (Figure 1). We included 42 RCTs, involving 21 studies 
(n=2,024) comparing CHD monotherapy with WM and 21 studies (n=1,850) comparing integration of CHD and WM 
(Int. CHD-WM with WM). According to the modified Jadad scale, totally 25 RCTs are at moderate risk of bias, 18 are 
at high risk of bias (see Supplementary Table 1). Study design details of each RCTs were shown in Supplementary 
Table 2, and the relationship among Chinese PinYin names, Chinese names, English names and Latin names of herbs 
mentioned in Supplementary Table 2 were demonstrated in Supplementary Table 3. 
 
Figure 1: Flow diagram of RCTs included (Note: RCT, randomized controlled trial) 
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Supplementary Table 1: Modified Jadad score of the included RCTs 
1. CHD vs. WM 
Trial Year Randomized Allocation concealment Blind Dropout Treatment based on TCM syndromes Modified Jadad score 
Wei BQ 2003 1 0 0 0 2 3 
Gong DH 2004 1 0 0 0 2 3 
Li JR 2005 1 0 0 0 2 3 
Wang HY 2005 1 0 0 0 1 2 
Wei YQ 2005 1 0 0 0 2 3 
Kan SY 2006 1 0 0 0 2 3 
Meng ZJ 2006 1 0 0 0 2 3 
Zhao HB 2006 1 0 0 0 0 1 
Chen YJ 2007 1 0 0 0 1 2 
Luo LB 2007 1 0 0 0 2 3 
Zhao M 2007 1 0 0 0 2 3 
Ou WE 2008 1 0 0 0 2 3 
Wang ZM 2008 1 0 0 0 2 3 
Xiao LD 2008 1 0 0 0 0 1 
Shi CH 2009 1 0 0 0 2 3 
Shu H 2009 1 0 0 0 2 3 
Su XH 2009 2 0 0 0 2 4 
Li LH 2010 1 0 0 0 0 1 
Meng L 2010 1 0 0 0 1 2 
Zhang YM 2011 1 0 0 0 2 3 
Zhu XP 2013 1 0 0 0 2 3 
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2. Int. CHD-WM vs. WM 
Trial Year Randomized Allocation concealment Blind Dropout Treatment based on TCM syndromes Modified Jadad score 
Wang HB 2003 1 0 0 0 0 1 
Yue WJ 2003 1 0 0 0 2 3 
Zhou AX 2006 1 0 0 0 2 3 
Shen Y 2007 1 0 0 0 0 1 
Xiang SY 2007 1 0 0 0 0 1 
Zhang DF 2008 1 0 0 0 0 1 
Gao Z 2009 1 0  0 0 1 
Huang GC 2009 1 0 0 0 1 2 
Lei CH 2009 1 0 0 1 2 4 
Ma J 2009 1 0 0 0 2 3 
Song FL  2009 1 0 0 0 2 3 
Liu HR 2010 2 0 0 0 0 2 
Kuang YJ 2011 1 0 0 0 2 3 
Wang XF 2011 1 0 0 0 2 1 
Li SQ 2012 1 0 0 0 2 3 
Zhang WH 2012 1 0 0 0 0 1 
Han XF 2013 1 0 0 0 2 3 
Wang J 2013 1 0 0 0 2 1 
Shan Q 2014 1 0 0 0 2 3 
Fu HK 2014 1 0 0 0 2 3 
Liu DX 2014 1 0 0 0 0 1 
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Supplementary Table 2: Study design details of the included RCTs 
1: CHD vs. WM 
Autho
r 
DOI/ 
Website 
Duration 
of clinical 
trail 
Year of 
publicatio
n 
Age 
[range] 
Participants 
(male/femal
e) 
Number of 
Interventio
n/ Control 
Intervention Control 
Duration of 
therapy 
Adverse 
events 
Zhu XP 
10.3969/j.issn
.1003-5699.2
007.03.015 
2003-2013 2013 [23, 67] 60 (43/17) 30/30 
Chai-Hu-Shu-Gan Decoction [ChaiHu 20g, DanShen 20g, 
FuLing 20g, NanShaShen 15g, BaiZhu 14g, TaiYangHua 
14g, ZeXie 14g, BaiShao 12g, ChiShao12g, RouDoukou 
12g, TanXiang 6g, HuangLian 6g, BanXia 6g, 
ZhiGanCao 6g] 
Domperidone, 
Bismuth 
Biskalcitrate, 
Triple therapy 
28 days 
Not 
reported 
Zhang 
YM 
10.3969/j.issn
.1006-0979.2
011.08.004 
2000-2010 2011 [28, 69] 120 (63/57) 60/60 
Tianqi 5g, BanXie 6g, GanCao 10g, HuangQin 10g, 
ZhiKe 10g, BaiShao 12g, PuGongYing 15g, DangGui 
15g, NanShaShen 15g, MaiDong 15g, BaiZhu 15g, 
DangShen 15g, DanShen 30g, HuangQi 45g 
Colloidal 
Bismuth Pectin, 
Metronidazole, 
Domperidone, 
Amoxicillin 
60 days 
Not 
reported 
Li LH 
http://www.c
nki.com.cn/A
rticle/CJFDT
OTAL-SCZY
201011038.ht
m 
2006-2009 2010 [33, 72] 55 (30/25) 30/25 
HuangQi 30g, TaiZiShen 30g, BaiZhu 20g, ShanYao 30g, 
NanShaShen 15g, YuZhu 15g, BaiHe 15g, MaiDong 20g, 
NvZhenZi 20g, LiChang 20g, DanShen 30g, PuHuang 
15g, GanCao 10g. 
Vitacoenzyme 
Tablets, 
Colloidal 
Bismuth Pectin, 
Compound 
Pepsin 
3 months 
Not 
reported 
Meng L 
http://www.c
nki.com.cn/A
rticle/CJFDT
otal-LZXB20
1004078.htm 
2004-2008 2010 [41, 72] 84 (57/27) 56/28 
Shan-Jia-Yu-Wei Decoction [PaoShanJia 6g, ZaoCi 10g, 
TongHuaGen 10g, ChaiHu 10g, FoShou 15g, ZhiKe 15g, 
TaoRen 10g, HongHua 10g, JiNeiJin 30g, JiaoSanXian 
30g, HuangLian l0g, WuZhuYu 3g, PuGongYing 10g, 
FuLing 30g, BaiZhu 30g, BaiJi 30g, BaiShao 15g, 
GanCao 6g] 
Vitacoenzyme 
Tablets, 
Domperidone 
60 days 
Not 
reported 
Shi CH 
10.3969/j.issn
.1671-038X.2
009.06.018 
2006-2009 2009 [17, 62] 76 46/30 
Jian-Pi-Yi-Wei Decoction [TaiZiShen 25g, BaiZhu 10g, 
MuXiang 10g, ShaRen 10g, BeiMu10g, PuHuang 15g, 
LianQiao 12g, MoYuGu 15g, MaiDong 10g, NanShaShen 
20g] 
Vitacoenzyme 
Tablets or 
Gefarnate. 
Patients with 
H.pylori 
infection: 
Tinidazole, 
Amoxicillin, 
Omeprazole, 
patients with 
bile 
regurgitation: 
Talcid, patients 
with 
gastrectasia: 
Domperidone 
90 days 
Not 
reported 
Su XH 
http://d.g.wan
fangdata.com.
cn/Periodical
2000-2008 2009 No data 120 (60/60) 62/58 
Gan-Cao-Xie-Xin Decoction [GanCao 10g, BanXie 12g, 
HuangQi 15g, HuangLian 10g, DangShen 30g, HuangQi 
30g, ShanYao 15g, ChaiHu 15g] 
Amoxicillin, 
Clarithromycin, 
Domperidone 
3 months 
Not 
reported 
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_cczyxyxb20
0906025.aspx 
Shu H 
10.3969/j.issn
.1005-7072.2
009.02.028 
2004-2007 2009 [24, 65] 58 (23/35) 30/28 
Shen-Shi-Yang-Wei Decoction [DangShen 20g, HuangQi 
30g, BaiZhu 15g, DanShen 30g, DangGui20g, ChiShao 
15g, GanCao 6g] 
Domperidone, 
Vitacoenzyme 
Tablets. Patients 
with H. pylori: 
De Nol, 
Amoxicillin 
intervention: 
69days, control: 
less than 4 
weeks 
Not 
reported 
Wang 
ZM 
10.3969/j.issn
.1009-5519.2
008.12.111 
2005-2007 2008 [34, 65] 78 (46/32) 45/33 
BanXie 12g, HuangLian 6g, HuangQi 12g, GanJiang 12g, 
TaiZiShen 20g, GanCao 9g, ChaiHu 12g, ZhiKe 15g, 
XiangFu 10g, ChuanXiong 12g, BaiShao 18g, MuXiang 
12g, ShaRen 10g, FoShou 12g, FoShou 12g 
Hydrotalcite 
tablet, 
Mosapride 
3 months 
Not 
reported 
Ou WE 
10.3969/j.issn
.1003-7705.2
008.02.015  
1994-2008 2008 No data 172 (106/66) 86/86 
YanHuSuo 15g, DanShen 15g, ShanZha 15g, Tianqi 3g, 
PuHuang 10g, DangGui 20g, BaiJi 20g, RuXiang 10g, 
WuYao 10g, BaiHe 30g, BaiShao 15g, ShiHu 15g, 
NanShaShen 15g, GanCao 5g 
Vitacoenzyme 
Tablets, 
Domperidone 
3 months 
one case 
reported 
urticaria in 
intervention 
Xiao LD 
10.3969/j.issn
.1673-7717.2
008.05.051 
2006-2007 2008 [19, 77] 60 (36/ 24) 30/30 
Wei-Yan Decoction [PuGongYing 30g, 
BaiHuaSheSheCao 30g, HuangLian 6g, HuangQi 10g, 
DanShen 20g, HuangQi 15g, BaiZhu 15g, FuLing 15g, 
BanXie 10g, ChenPi 10g, WaLengZi 30g, MoYuGu 30g, 
JiangHuang 15g, GanJiang 8g] 
Omeprazole, 
Clarithromycin, 
Amoxicillin 
intervention: 20 
days, control: 7 
days 
Not 
reported 
Chen YJ 
10.3969/j.issn
.1006-6233.2
007.03.030 
2000-2006 2007 [23, 70] 92 (49/43) 50/42 
Jian-Pi-Yang-Ying-He-Wei Decoction [TaiZiShen, 
WuZhiMaoTao, ShiHu, FoShou, YanHuSuo, 
NanShaShen, BaiJi, DanShen, MaiDong] 
Marzulene S 24 weeks 
Not 
reported 
Luo LB 
10.3969/j.issn
.1000-7369.2
007.09.032 
2002-2006 2007 [25, 73] 82 (55/27) 42/40 
Man-Wei-Ning Decoction [DangShen 15g, WuZao 15g, 
ZhiKe 10g, DangGui 10g, BaoShao 20g, HuangQi 20g, 
YanHuSuo 12g, GanCao 6g, TianQi 4g] 
Bismuth 
Potassium 
Citrate Capsules 
8 weeks 
six cases 
reported 
nausea, 
vomit or 
constipatio
n in control 
Zhao M 
10.3969/j.issn
.1000-7369.2
007.09.029 
2007 2007 [31, 50] 64 32/32 
(1) For TCM syndrome of Weakness of Spleen and 
Stomach: HuangQi 15g, DangShen 15g, BaiZhu 10g, 
FuLing 10g, BaiShao 10g, GanCao 10g, ShengJiang 10g, 
DaZao 6g, ShaRen 6g, (2) for TCM syndrome of Coke 
and Blood Stasis: BanXie 10g, ChenPi 6g, HouPu 12g, 
ZhiKe 10g, WuLingZhi 12g, ChuanXiong 10g, DanShen 
20g, YanHuSuo 20g, (3) for TCM syndrome of 
Deficiency of Stomach-Ying: NanShaShen 15g, MaiDong 
12g, DiHuang 12g, DangGui15g, ShiHu 10g, BaiShao 
10g, WuMei 15g, GanCao 6g. 
Amoxicillin, 
Chinese 
Goldthread 
Rhizome, 
Colloidal 
Bismuth 
Pectin1, 
Domperidone 
8 weeks 
Not 
reported 
Meng ZJ 
10.3969/j.issn
.1005-5304.2
006.04.028 
1998-2005 2006 [27, 70] 135 75/60 
Wei-Shu Decoction [HuangQi 45g, DangShen 15g, 
BaiZhu 15g, ZhiKe 10g, MaiDong 15g, NanShaShen 15g, 
DangGui15g, BaiShao 12g, HuangQi 10g, PuGongYing 
15g, BanXie 6g, DanShen 30g, TianQi 5g, GanCao 10g] 
Amoxicillin, 
Metronidazole, 
Colloidal 
Bismuth 
Pectin1, 
Domperidone 
8 weeks 
Not 
reported 
Kan SY 10.3969/j.issn 1997-2005 2006 [31, 64] 110 (65/45) 70/40 Yang-Ying-Rong-Wei-Wan [DiHuang, BeiShaShen, Vitacoenzyme 90 days Not 
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.0257-358X.2
006.02.008 
DangGui, ShouWuTeng, HuangLian, BaiShao, GouQiZi, 
MaiDong, BanXie, JiangHuang, BianDou, GanCao, 
MaiYa] 
Tablets reported 
Zhao HB 
10.3969/j.issn
.1000-3649.2
006.09.037 
2001-2005 2006 [18, 58] 90 (52/38) 49/41 
Wei-Ling-San [CaoGuo 70g, WuLingZhi 70g, RuXiang 
65g, MoYao 65g, GuaLou 85g, BaiHuaSheSheCao 85g, 
HuangLian70g, BanXie 50g] 
Sucralfate, 
Metronidazole 
2 months 
Not 
reported 
Li JR 
10.3969/j.issn
.1000-1719.2
005.02.018 
2004 2005 [31, 51] 72 36/36 
(1) For TCM syndrome of Weakness of Spleen and 
Stomach: HuangQi 15g, DangShen 15g, BaiZhu 10g, 
FuLing 10g, BaiShao 10g, GuiZhi 6g, GanCao 10g, 
ShengJiang 10g, DaZao 6, ShaRen 6g, (2) for TCM 
syndrome of Coke and Blood Stasis: BanXie 10g, ChenPi 
6g, FuLing 10g, HouPu 12g, BaiZhu 15g, WuLingZhi 
12g, ChuanXiong 10g, YanHuSuo 20g, SanLeng 10g, 
JiangHuang 10g, GanCao 10g, DanShen 20g, YiYiRen 
10g, ShaRen 6g, (3) for TCM syndrome of Deficiency of 
Stomach-Ying: NanShaShen 15g, MaiDong 12g, DiHuang 12g, 
DangGui15g, BaiShao 10g, ShiHu 10g, WuMei 15g, GanCao 6g 
Amoxicillin, 
Chinese 
Goldthread 
Rhizome, 
Colloidal 
Bismuth 
Pectin1, 
Domperidone 
8 weeks 
Not 
reported 
Wang HY 
10.3969/j.issn.1
000-1719.2005.
12.037 
2005 2005 [26, 63] 130 (7 /56) 100/30 
Shen-Ji-Yang-Wei Decoction [HuangQi 15g, NanShaShen 10g, 
BaiShao 15g, YanHuSuo 10g, DanShen 10g, BaiJi 8g, BeiMu15g, 
GanCao 5g] 
Omeprazole, 
Amoxicillin, 
Metronidazole 
4 weeks Not reported 
Wei YQ 
10.3969/j.issn.1
004-745X.2005.
12.067 
1990-2003 2005 [31, 65] 90 (54/36) 54/36 
TaiZiShen 50g, HuangQi 50g, FuLing 30g, BaiZhu 12g, DanShen 
15g, JiangHuang 15g, MuGua 12g, WuMei 9g, ChaiHu 9g, 
BaiHuaSheSheCao 30g 
Bismuth 
Potassium Citrate 
Capsules, 
Amoxicillincapsul
e, Vitacoenzyme 
Tabletstablet, 
Domperidone 
tablet. 
6 months Not reported 
Gong DH 
10.3969/j.issn.1
672-951X.2004.
12.008 
1998-2004 2004 [16, 67] 100 (58/42) 50/50 
HuangQi 15g, BaiZhu 10g, FuLing 10g, NanShaShen 15g, 
MaiDong 15g, E’Jiao 10g, PuGongYing 15g, BaiHuaSheSheCao 
15g, WuLingZhi 10g, PuHuang 10g, ZhiKe 10g, ShanZha 10g 
Vitacoenzyme 
Tabletstablet, 
Folic Acidtablet, 
domperidone 
2-4 months Not reported 
Wei BQ 
10.3969/j.issn.0
256-7415.2003.
12.015 
1998-2002 2003 No data 176 ( 95/81) 96/80 
Wei-Ling Decoction [DangShen15g, FuLing, DanShen 15g, 
XiangFu 15g, JiaoSanXian 15g, PuGongYing 15g, GaoLiangJiang 
10g, NvZhenZi 10g, BaiShao 10g, GuiZhi 10g, GanCao 6g, 
HuangQi 30g, BaiZhu 12g] 
Patients with 
gastrectasia: 
Cisapride or 
Domperidone; 
patients with 
stomach-ache: 
Compound 
Belladonna 
Mixture, patients 
with anemia: 
Vitamin B and 
Folic Acid; 
patients with 
H.pylori infection: 
Amoxicillin, 
metronidazole, 
Colloidal Bismuth 
Pectin 
45 days Not reported 
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2: Int. CHD-WM vs. WM 
 
Author 
DOI/ 
Website 
Duration of 
clinical trail 
Year of 
publication 
Age 
[range] 
Participants 
Number of 
Intervention/ 
Control 
Intervention Control 
Duration 
of therapy 
Adverse 
events 
Fu HK 
http://lib.cqvi
p.com/qk/939
43A/201403/
48935322.ht
ml 
2010-2012 2014 [25, 69] 50 (19/31) 25/25 
WM: Omeprazole, Amoxicillin, Clarithromycin 
Omeprazole, 
Amoxicillin, 
Clarithromycin 
N/R 
Not 
reported 
CHD: DangShen 10g, DiHuang 10g, WuLingZhi 
10g, PuHuang 10g, TaiZiShen 20g, GanCao 6g, 
CHD: HuangQi 30g, BaiZhu 12g, NanShaShen 15g, 
MaiDong 15g 
Liu DX 
10.3969/j.issn
.1004-437X2
014.01.055 
2010-2012 2014 [33, 36]  80 (59/21) 40/40 
WM: Omeprazole, Vatacoenayme, Tinidazole, 
Clarithromycin 
Omeprazole, 
Vatacoenayme, 
Tinidazole, 
Clarithromycin 
2 months 
Not 
reported 
CHD: HuangQi 15g, DangShen 10g, BaiShao 10g, 
NanShaShen 10g, DangGui10g, PuHuang 10g, 
WuLingZhi 10g, PuHuang 10g, ZhiGanCao 5g 
Shan Q 
10.3969/j.issn
.1004-7484(x
).2014.06.038 
2011-2013 2014 [38, 42] 112 (31/27) 54/58 
WM: Thiazole, PPI, Triple therapy or Quadruple 
therapy 
Thiazole, PPI, Triple 
therapy or Quadruple 
therapy 
6 months 
Not 
reported 
CHD: for patients with stagnation of liver-QI and 
stomach-QI: Chai-Hu-Shu-Gan-San; for patients with 
epigastralgia: Hua-Gan-Jian-He-Zuo-Jin-Wan; for 
patients with damp heat in the spleen and the 
stomach: Huang-Lian-Wen-Dan Decoction; for 
patients with weakness of the spleen and the stomach: 
Liu-Jun-Zi Decoction; for patients with Stomach yin 
deficiency: NanShaShen, MaiDong Decoction; 
patients with stomach and blood stasis: DanShen 
Decoction 
Wang J 
10.3969/j.issn
.1009-4393.2
013.6.109 
2011-2012 2013  [22, 79] 128 (74/54) 64/64 
WM: Vatacoenayme, Bismuth Biskalcitrate, 
Amoxicillin, Tinidazole, Domperidone Vatacoenayme, Bismuth 
Biskalcitrate, 
Amoxicillin, Tinidazole, 
Domperidone 
2 months 
Not 
reported 
CHD: DangShen 20g, BaiZhu 15g, HuangQi 20g, 
BaiShao 15g, FuLing 15g, DanShen 20g, DangGui 
12g, YanHuSuo 15g, ShaRen 10g, TianQi 3g, E'Zhu 
10g, MuXiang 10g, ChaiHu 10g 
Han 
XF 
http://d.wanfa
ngdata.com.c
n/Periodical/j
kbd-x201308
126 
2010-2012 2013 [37, 78] 40 (19/27) 20/20 
WM: Vatacoenayme, Amoxicillin 
Vatacoenayme, 
Amoxicillin 
4 months 
Not 
reported 
CHD: Yi-Wei-Suo-Xing-Wei-Yan Decoction: 
DangShen 30g, PuGongYing 30g, ChuanXiong 10g, 
HuangQi30g, E’Zhu 10g, JiNeiJin 15g, TianQi 3g, 
DanShen 20g, DaHuang 5g, HouPu 5g, YanHuSuo 
15g 
Li SQ 
doi： 
10.3969/j.issn
1007-8231.20
12.11.067 
2011 2012 [30, 65] 59 (41/17) 29/29 
WM: Vatacoenayme, Colloidal Bismuth, 
Amoxicillin, Tinidazole, Domperidone Vatacoenayme, Colloidal 
Bismuth, Amoxicillin, 
Tinidazole, 
Domperidone 
4 weeks 
Not 
reported 
CHD: HuangQi 30g, DangShen 20g, BaiZhu 10, 
FuLing 10g, BaiShao 15g, MaiDong 15g, ShiHu 15g, 
DiHuang 30g, E’Zhu 15g, FoShou 15g, QingDai 3g, 
ZhiGanCao 9g 
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Zhang 
WH 
http://d.wanfa
ngdata.com.c
n/Periodical/j
kbd-z201208
150 
2005-2010 2012 [28, 72] 120 68/52 
WM: Tinidazole, Clarithromycin, Domperidone, 
Vatacoenayme 
Tinidazole, 
Clarithromycin, 
Domperidone, 
Vatacoenayme 
2 months 
Not 
reported 
CHD: NanShaShen 10g, MaiDong 10g, ShiHu 10g, 
ZeXie 10g, BaiZhu 10g, BaiShao 10g, TaiZiShen 
15g, DanShen 15g, HuangQi 12g, ShanYao 15g, 
FoShou 6g, MuXiang 6g, ShaRen 5g, ShengMa 6g, 
Dihuang 10g 
CHD: Wen-Yang-Hua-Tan Decoction: HuangQi 50g, 
YiYiRen 20g, DangShen 20g, BaiZhu 15g, FuLing 
15g, GuiPi 10g, DingXiangZhi 10g, HuoXiang 10g, 
PeiLan 10g, ShaRen 5g 
Wang 
XF 
http://www.c
qvip.com/QK
/87361X/201
103/1003588
945.html 
2009-2010 2011 [19, 72] 136 (78/58) 68/68 
WM: Vatacoenayme, Omeprazole, Metronidazole, 
Amoxicillin 
Vatacoenayme, 
Omeprazole, 
Metronidazole, 
Amoxicillin 
6-8 weeks 
control: 12 
patients 
with 
gastrointesti
nal adverse 
reaction, 
such as 
nausea, 
vomiting, 
abdominal 
distention; 
intervention
: six patients 
with minor 
gastrointesti
nal adverse 
reaction 
CHD: Wen-Yang-Hua-Tan Decoction: HuangQi 50g, 
YiYiRen 20g, DangShen 20g, BaiZhu 15g, FuLing 
15g, ShengJiang 10g, GuiZhi 10g, DingXiangZhi 
10g, HuoXiang 10g, PeiLan 10g, ShaRen 5g 
Kuang 
YJ 
doi:10.3969/j.
issn.1009-439
3.2011.19.10
1 
2008-2010 2011 [21, 67] 120 (76/44) 60/60 
WM: Bismuth Biskalcitrate, Omeprazole, 
Clarithromycin, Amoxicillin, Domperidone Bismuth Biskalcitrate, 
Omeprazole, 
Clarithromycin, 
Amoxicillin, 
Domperidone 
N/R 
no patient 
with 
adverse 
reaction 
both in 
control and 
intervention 
CHD: TianQi 3g, ZhiGanCao 5g, WuZhuYu 5g, 
ShaRen 6g, HuangLian 6g, NanShaShen 6g, 
DangGui 10g, BaiZhu 10g, HouPu 10g, HuangQi 
15g, FuLing 15g, DangShen 20g, ShanYou 20g 
Liu HR 
http://www.c
qvip.com/QK
/71135X/201
107/3489634
6.html 
2003-2007 2010 [30, 63] 100 (59/41) 50/50 
WM: Omeprazole, Clarithromycin, Tinidazole;  
Omeprazole, 
Clarithromycin, 
Tinidazole 
6 months 
Not 
reported 
CHD: Wei-Shu-Jian-Ji [ChaiHu, BaiShao, GanCao, 
ZhiKe, DaHuang, PuGongYing, FuLing, BaiZhu, 
ChuanLianZi, YanHuSuo, LiYa, DanShen] 
Gao Z 
http://www.c
qvip.com/Mai
n/Detail.aspx
?id=3142227
6 
1999-2007 2009 [25, 72] 83 (54/29) 46/37 
WM: Colloidal Bismuth Pectin Vitacoenzyme 
Compound Pepsin;  
Colloidal Bismuth Pectin 
Vitacoenzyme 
Compound Pepsin; 
12 months 
Not 
reported 
CHD: Zi-Yin-Hua-Yu-Ning-Wei Decoction 
[TaiZiShen 20g, BaiShao 20g, ShiHu 15g, WuMei 
15g, GanCao 10g, E’Zhu 10g, ZiSuGeng 10g, TianQi 
6g, HuangYaoZi 12g, ChuanLianZi 9g] 
Lei CH http://www.c 2009 2009 [33, 65] 68 34/34 WM: Metronidazole, Folic Acid;  Metronidazole, Folic 24 weeks Not 
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nki.com.cn/A
rticle/CJFDT
otal-SYBD20
0904007.htm 
CHD: Si-Jun-Zi Decoction [RenShen 9g, BaiZhu 9g, 
FuLing 9g, WuLingZhi 8g, ChuanXiong 8g, 
BaiHuaSheSheCao 10g, GanCao 6g] 
Acid reported 
Ma J 
http://www.c
qvip.com/Mai
n/Detail.aspx
?id=3064830
2 
2007-2008 2009 [30, 65] 60 (31/29) 30/30 
WM: Omeprazole, Clarithromycin, Amoxicillin;  
Omeprazole, 
Clarithromycin, 
Amoxicillin, Vitamin E, 
Carotene 
3 months 
Not 
reported 
CHD:Jian-Pi-Yi-Wei Decoction [HuangQi 20g, 
Dangshen 20g, BaiZhu 15g, GuiZhi 10g, DanShen 
15g, ChiShao15g, ShanZha 10g, BaiShao 15g, E’Zhu 
10g, GanCao 5g] 
Huang 
GC 
10.3969/j.issn
.1672-2779.2
009.04.071 
2004-2007 2009 [30, 81] 85 (58/27) 45/40 
WM: Colloidal Bismuth Pectin capsule;  
Colloidal Bismuth Pectin 
capsule 
12 weeks 
Not 
reported 
CHD: Ban-Xia-Xie-Xin Decoction [BanXie 10g, 
Dangshen 20g, HuangLian6g, HuangQi 10g, 
GanJiang 5g, GanCao 6g, PuGongYing 15g, ZhiKe 
10g, MoYuGu 15g, BaiHuaSheSheCao 15g] 
CHD: for TCM syndrome of Weakness of Spleen and 
Stomach: Dangshen, HuangQi, ShanYao, GanCao, 
BaiZhu, GanJiang, NanShaShen, DaZao; for TCM 
syndrome of Liver Stomach Disharmony: ChaiHu, 
MuXiang, FoShou, BaiShao, NanShaShen, MaiDong, 
YuZhu, HuangLian, ShiHu, GanCao, YanHuSuo, 
Reed Rhizome; for TCM syndrome of Stagnation of 
Phlegm: ChenPi, FuLing, BanXie, BaiZhu, HouPu, 
HuangQi, GanJiang, GanCao; for TCM syndrome of 
Damp-Heat in Spleen and Stomach: HuangLian, 
HuangQi, PuGongYing, BanXie, ZhuRu, FuLing, 
YiYiRen, ZeXie, FoShou, ChenPi, ZhiKe; for TCM 
syndrome of Stomach Collateral Stasis: YanHuSuo, 
MoYao, WuLingZhi, CaoGuo, DanShen, ChiShao, 
E’Zhu, PuHuang, TaoRen. 
Song 
FL 
http://lib.cqvi
p.com/qk/910
70A/200903/
29592636.ht
ml 
2005-2007 2009 [33, 65] 68 (41/27) 34/34 
WM: Metronidazole, Folic Acid;  
Metronidazole, Folic 
Acid 
24 weeks 
Not 
reported 
CHD: Jia-Wei-Si-Jun-Zi Decoction [Dangshen 9g, 
BaiZhu 9g, FuLing 9g, WuLingZhi 8g, ChuanXiong 
8g, BaiHuaSheSheCao 6g, GanCao 6g] 
Zhang 
DF 
10.3969/j.issn
.1001-6910.2
008.03.016 
1999-2006 2008 [45, 70] 70 (41/29) 36/34 
WM: Omeprazole capsule, Amoxicillin capsule, 
Metronidazole tablet, Folic Acid;  
Omeprazole capsule, 
Amoxicillin capsule, 
Metronidazole tablet, 
Folic Acid 
60-150 
days 
Not 
reported 
CHD: Dan-shen-Yin plus Chai-Shao-Liu-Jun-Zi 
Decoction [HuangQi 3g, RenShen 6g, FuLingg, 
BaiZhu 6g, DanShen 3g, DangGui12g, TanXiang 6g, 
ShaRen 6g, BanXie 6g, MuXiang 6g, BaiShao 12g, 
ChaiHu 10g, HuangQi 12g, GanCao 3g] 
Shen Y 
10.3969/j.issn
.1001-9448.2
007.03.068 
2000-2006 2007 [17, 75] 132 (82/50) 69/63 
WM: Bismuth Potassium Citrate Capsules, 
Domperidone, Weilesheng tablet, Cimetidine, 
metronidazole, Amoxicillin 
Bismuth Potassium 
Citrate Capsules, 
Domperidone, 
Weilesheng tablet, 
Cimetidine, 
3 months 
two cases 
reported 
rash in 
intervention 
CHD: Dan-Shen-Yin plus Shi-Xiao-San [DanShen 
30g, YanHuSuo 10g, TanXiang 10g, ShaRen 5g, 
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ZiSuGeng 10g, JuLuo 10g, DaHuang 5g, GanCao 3g, 
PuHuang 10g, WuLingZhi 10g] 
metronidazole, 
Amoxicillin  
Xiang 
SY 
10.3969/j.issn
.1671-4040.2
007.05.007 
2007 2007 [37, 68] 130 (72/58) 80/50 
WM: Sucralfate tablet, Mosapride, Folic Acid; 
Sucralfate tablet, 
Mosapride, Folic Acid 
3 months 
Not 
reported 
CHD: Fu-Fang-Wu-Shen Decoction [Dangshen 15g, 
NanShaShen 12g, XuanShen 10g, DanShen 10g, 
KuShen 10g, MaiDong 15g, HuangJing 10g, 
ChuanXiong 10g, HuangLian 10g, HuangQi 12g, 
ShiHu 15g, JinFeiCao 10g] 
Zhou 
AX 
http://192.168
.89.197:8012/
ArticleDetail.
aspx?id=2190
6480 
2004-2006 2006 [29, 71] 60 (30/30) 30/30 
WM: one chosen from Omeprazole, Lansoprazole, 
Bismuth Potassium Citrate, plus one chosen from 
Clarithromycin, Amoxicillin, Metronidazole 
One chosen from 
Omeprazole, 
Lansoprazole, Bismuth 
Potassium Citrate, plus 
one chosen from 
Clarithromycin, 
Amoxicillin, 
Metronidazole. 
2 months 
Not 
reported 
CHD: Bu-Yi-Ha-Yu Decoction [HuangQi 30g, 
TaiZiShen 30g, NanShaShen 20g, MaiDong 20g, 
DangGui20g, DiHuang 30g, E’Zhu 10g, HongHua 
6g, MoYao 10g, BaiHuaSheSheCao 30g] 
Wang 
HB 
10.3870/j.issn
.1004-0781.2
003.11.010 
1999-2000 2003 
54 
patients >4
0, 11 
patients 
<40:  
65 35/30 
WM: Colloidal Bismuth Pectin, Amoxicillin, 
Furazolidone;  
Colloidal Bismuth 
Pectin, Amoxicillin, 
Furazolidone 
4 weeks 
Not 
reported 
CHD: Wei-Fu-Jian-Ji [TaoRen 10g, HongHua 10g, 
ChuanXiong 10g, ChiShao10g, PuGongYing 10g, 
MuXiang 10g, GanCao 10g, HuangQi 20g, Dangshen 
15g] 
Yue 
WJ 
1998-2003 2003 [31, 79] 85 (49/36) 58/27 
WM: Colloidal Bismuth Pectin capsule, Tinidazole 
tablet, Vitamin C tablet, Folic Acid tablet;  
Colloidal Bismuth Pectin 
capsule, Tinidazole 
tablet, Vitamin C tablet, 
Folic Acid tablet 
6 weeks 
Not 
reported 
10.3760/cma.j
.issn.1008-67
06.2003.11.0
55 
CHD: Xiang-Sha-Liu-Jun-Zi Decoction [XiangFu 
15g, ShaRen 10g, RenShen 15g, BaiZhu 20g, FuLing 
15g, GanCao 10g, ChenPi 10g, BanXie 10g] 
CHD: Chu-Pi-Yang-Wei Decoction: [Dangshen l5g, 
FuLing 15g, E’Zhu l5g, WuZhuYu 6g, MuXiang 9g, 
GanCao 6g, HuangJing 15g , ShanYao 30g, ShaRen 
6g, HuangLian 6g, BaiJiangCao 30g] 
 
 
Fang et al., Afr J Tradit Complement Altern Med., (2017) 14 (4): 297-319 
https://doi.org/10.21010/ajtcam.v14i4.33   
 
309 
 
 
Supplementary Table 3: List of traditional Chinese herbs used in included studies 
Pinyin Name 
Chinese 
Name 
Latin Name English Name 
BaiHe 百合 Lilium brownii var. viridulum Greenish lily bulb 
BaiHuaSheSheCao 白花蛇舌草 Hedyotis diffusa Spreng. Spreading hedyotis herb 
BaiJi 白及 Bletilla striata (Thunb.) Rchb.f. Common bletilla tuber 
BaiJiangCao 败酱草 Hlaspi arvense L Dahurian patrinia herb 
BaiShao 白芍 Paeonia lactiflora Pall. White peony root 
BaiZhu 白术 Atractylodes macrocephala Koidz Largehead atractylodes rhizome 
BanXie 半夏 Pinellia ternata (Thunb.) Breit. Ternate pinellia 
BeiMu 贝母 Fritillaria cirrhosa D.Don Fritillaria  
BeiShaShen 北沙参 Glehnia littoralis F.Schmidt ex Miq. Coastal glehnia root 
BianDou 扁豆 Lablab purpureus (L.) Sweet Dolichos lablab 
CaoGuo 草果 Amomum tsao-ko Crevost & Lemarié Tsao-ko amomum fruit 
ChaiHu 柴胡 Bupleurum chinense DC. Chinese thorowax root 
ChenPi 陈皮 Clausena lansium (Lour.) Skeels Tangerine peel 
ChiShao 赤芍 
Paeonia anomala subsp. veitchii (Lynch) 
D.Y.Hong & K.Y.Pan 
Red peony root  
ChuanXiong 川芎 Cortia striata (DC.) Leute Szechwan lovage rhizome 
ChuanLianZi 川楝子 Melia toosendan Siebold & Zucc Szechwan chinaberry fruit 
DaHuang 大黄 Rheum palmatum L. Rhubarb 
DangGui 当归 Angelica sinensis (Oliv.) Diels Chinese angelica  
Fang et al., Afr J Tradit Complement Altern Med., (2017) 14 (4): 297-319 
https://doi.org/10.21010/ajtcam.v14i4.33   
 
310 
 
 
DangShen 党参 Codonopsis pilosula (Franch.) Nannf. Codonopsis pilosula 
DanShen 丹参 Salvia miltiorrhiza Bunge Dan-shen root 
DaZao 大枣 Ziziphus jujuba Mill Common jujube 
DiHuang 地黄 
Rehmannia glutinosa (Gaetn) Libosch. ex Fisch. 
et Mey 
Rehmannia root 
DingXiangZhi 丁香枝 Syzygium aromaticum (L.) Merr.Et Perry Clovetree twig 
E'Jiao 阿胶 Colla Corii Aaini Ass-hide gelatin 
E'Zhu 莪术 Curcuma zedoaria (Christm.) Roscoe  Rhizoma curcumae 
FoShou 佛手 
Citrus medica var. sarcodactylus (Siebold ex 
Hoola van Nooten) Swingle  
Finger citron fruit 
FuLing 茯苓 Poria cocos Wolf [Fungi] Indian buead 
GanCao 甘草 Glycyrrhiza uralensis Fisch. Liquorice root 
GanJiang 干姜 Zingiber officinale Roscoe Dried ginger 
GaoLiangJiang 高良姜 Alpinia officinarum Hance Lesser galangal rhizome 
GouQiZi 枸杞子 Lycium barbarum L. Barbury wolfberry fruit 
GuaLou 瓜蒌 Trichosanthes kirilowii Maxim Mongolian snakegourd fruit  
GuiZhi 桂枝 Cinnamomum cassia (L.) J.Presl Cassiabarktree twig 
HongHua 红花 Carthamus tinctorius L. Safflower 
HouPu 厚朴 Citrus grandis (L.) Osbeck Officinal magnolia bark 
HuangJing 黄精 Polygonatum sibiricum F.Delaroche  Siberian solomonseal rhizome 
HuangLian 黄连 Coptis chinensis Franch. Chinese goldthread rhizome  
HuangQi 黄芪 Astragalus membranaceus (Fisch.) Bunge Astragalus membranaceus 
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HuangQin 黄芩 Scutellaria Linn. Radix scutellariae 
HuangYaoZi 黄药子 Dioscorea bulbifera L. Airpotato yam rhizome 
HuoXiang 藿香 Agastache rugosa (Fisch. & C.A.Mey.) Kuntze Agastache rugosus  
JiangHuang 姜黄 Curcuma longa L. Turmeric rhizome 
JiaoSanXian 焦三仙 
Hordeum vulgare L Plus Crataegus pinnatifida 
Bunge Plus Massa Medicata Fermentata 
Stir-baking fructus hordei 
germinatus et crataegt et massa 
fer-mentata medicinalis 
JiNeiJin 鸡内金 Gallus gallus domesticus Brisson  Corium stomachichum galli 
JinFeiCao 金沸草 Inula japonica Thunb. Inula flower 
JuLuo 桔络 Citrus reticulata Blanco Tangerine pith 
KuShen 苦参 Sophora flavescens Aiton Lightyellow sophora root 
LianQiao 连翘 Forsythia suspensa (Thunb.) Vahl Weeping forsythia fruit 
LiChang 鳢肠 Eclipta prostrata (L.) L. Eclipta prostrata 
LiYa 粟芽 Setaria italica (L.) P.Beauv. Foxtail millet sprout 
MaiDong 麦冬 Ophiopogon japonicus (Thunb.) Ker Gawl. Dwarf lilyturf root tuber 
MaiYa 麦芽 Hordeum vulgare L Malt 
MoYao 没药 Commiphora myrrha (Nees) Engl. Myrrh  
MoYuGu 墨鱼骨 Sepia esculenta Hoyle Cuttlebone 
MuGua 木瓜 Chaenomeles chinensis (Dum.Cours.) Koehne Common floweringquine fruit 
MuXiang 木香 Rosa banksiae R.Br. Costusroot 
NanShaShen 南沙参 Adenophora tetraphylla (Thunb.) Fisch. Upright ladybell root 
NvZhenZi 女贞子 Ligustrum lucidum W.T.Aiton Glossy privet fruit 
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PaoShanJia 炮山甲 Squama Manis Parched pangolin scales 
PeiLan 佩兰 Eupatorium fortunei Turcz. Eupatorium fortunei 
PuGongYing 蒲公英 Taraxacum mongolicum Hand.-Mazz. Mongolian dandelion herb 
PuHuang 蒲黄 Typha angustifolia L. Cattail pollen 
QingDai 青黛 Baphicacanthus cusia (Nees) Bremek Indigo naturalis 
RenShen 人参 Panax ginseng C.A.Mey. Ginseng  
RouDoukou 肉豆蔻 Myristica fragrans Houtt. Fructus amomi rotundus 
RuXiang 乳香 Boswellia carteri Birdw. Frankincense  
SanLeng 三棱 
Sparganium stoloniferum (Buch.-Ham. ex 
Graebn.) Buch.-Ham. ex Juz 
Common burreed tuber 
ShanYao 山药 Dioscorea oppositifolia L. Common yam rhizome 
ShanZha 山楂 Crataegus scabrifolia (Franch.) Rehder Chinese hawthorn fruit 
ShaRen 砂仁 Amomum villosum Lour. Villous amonmum fruit 
ShengJiang 生姜 Zingiber officinale Roscoe Fresh ginger 
ShengMa 升麻 Cimicifuga foetida L. Rhizoma cimicifugae 
ShiHu 石斛 Dendrobium catenatum Lindl Noble dendrobium stem herb 
ShouWuTeng 首乌藤 Fallopia multiflora (Thunb.) Harald Tuber fleeceflower stem and leaf 
TaiYangHua 太阳花 Portulaca grandiflora Portulaca grandiflora 
TaiZiShen 太子参 Pseudostellaria heterophylla (Miq.) Pax Pseudostellaria root 
TanXiang 檀香 Gaultheria fragrantissima Wall Sandalwood 
TaoRen 桃仁 Prunus persica (L.) Batsch Peach seed 
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Tianqi 田七 
Panax pseudoginseng var. notoginseng (Burkill) 
G.Hoo & C.L.Tseng  
Pseudo-ginseng 
TongHuaGen 通花根 Tetrapanax papyrifer (Hook.) K.Koch Ricepaperplant 
WaLengZi 瓦楞子 Concha Arcae Arc shell 
WuLingZhi 五灵脂 Faeces Trogopterpri Trogopterus dung 
WuMei 乌梅 Prunus mume (Siebold) Siebold & Zucc. Smoked plum 
WuYao 乌药 Lindera aggregata (Sims) Kosterm. Combined spicebush root  
WuZao 乌枣 Diospyros lotus L. Smoked jujube 
WuZhiMaoTao 五指毛桃 Ficus simplicissima Lour. Radix fici simplicissimae 
WuZhuYu 吴茱萸 Tetradium ruticarpum (A.Juss.) T.G.Hartley Medicinal evodia immature fruit 
XiangFu 香附 Cyperus rotundus L. Nutgrass galingale rhizome 
XuanShen 玄参 Scrophularia oldhamii Oliv. Figwort root 
YanHuSuo 延胡索 Corydalis yanhusuo Yanhusuo tuber 
YiYiRen 薏苡仁 Coix lacryma-jobi L. Ma-yuen jobstears seed 
YuZhu 玉竹 Polygonatum odoratum (Mill.) Druce Fragrant solomonseal rhizome 
ZaoCi 皂刺 Gleditsia sinensis Lam. Spina gleditsiae 
ZeXie 泽泻 Alisma plantago-aquatica L. Rhizoma alismatis 
ZhiGanCao 炙甘草 Glycyrrhiza uralensis Fisch. Prepared liquorice root 
ZhiKe 枳壳 Citrus × aurantium L. Submature bitter orange 
ZhuRu 竹茹 Sinocalamus beecheyanus (Munro) McClure Bamboo shavings 
ZiSuGeng 紫苏梗 Perilla frutescens (L.) Britton Caulis perillae acutae 
 
Eradication of H. pylori 
 
There were 12 trials reporting the eradication rate of H. pylori. Remission of H. pylori infection was not achieved in 
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121 (21.8%) of 554 patients randomized to receive CHD (alone or integrated with WM), compared with 180 (38.2%) of 
471 patients received WM (RR=1.29; 95% CI 1.11-1.50) with significant heterogeneity between studies (I2=71%) 
(Figure 2). There was statistically significant funnel plot asymmetry (Egger’s test p=0.044), suggesting evidence of 
publication bias or other small study effects. 
In subgroup of CHD monotherapy versus WM, six trials reported the eradication rate of H. pylori. There was no 
significant difference between CHD and WM in H. pylori eradication (RR=1.12, 95% CI 0.95-1.32) (Figure 2), with 
significant heterogeneity between studies (I2=59%). However, the pooled data suggested that CHD with WM had 
beneficial effect over WM (RR=1.52, 95% CI 1.14-2.02), with significant heterogeneity between studies (I2=76%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Efficacy of CHD compared with WM in eradication of H. pylori 
Note: CHD, Chinese herbal decoction; WM, western medicine; Int. CHD-WM, integrated Chinese herbal decoction 
and western medicine; 95% CI, 95% confidence interval. Each point on the figure represents a relative risk (RR). The 
diamond represents the pooled estimate of effect, as calculated according to the random effects model. RR<1 means 
numerically lower response rate than WM, and RR>1 numerically higher response rate than WM. 95% CI doesn’t 
include the number 1 means statistical difference between the two groups. 
 
Clinical manifestations improvement 
 
In total, 38 trials compared CHD (alone or integrated with WM) with WM involving 3,812 patients reported 
clinical manifestations improvement rate. There are 173 (8.3%) of 2,091 assigned to CHD (alone or integrated with 
WM) who failed to improve clinical manifestations, compared with 503 (28.8%) of 1,747 patients allocated to WM 
(RR=1.28; 95% CI 1.22-1.34), without significant heterogeneity between studies (I2=44%) (Figure 3). Evidence of 
publication bias was observed (Egger’s test p=0.000). 
In subgroup of CHD monotherapy versus WM, 25 studies reported the clinical manifestations improvement rate. 
The pooled data suggested that CHD had beneficial effect over WM (RR=1.28, 95% CI 1.22-1.35), without significant 
heterogeneity between studies (I2=34%). While Int. CHD-WM was found to be beneficial over WM alone (RR=1.27, 
95% CI 1.16-1.39), with significant heterogeneity between studies (I2=60%). There was statistically significant funnel 
plot asymmetry in the two subgroups (Egger’s test p=0.0017, p=0.0019, respectively), suggesting evidence of 
publication bias. 
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Figure 3: Efficacy of CHD compared with WM in clinical manifestations improvement 
Note: CHD, Chinese herbal decoction; WM, western medicine; Int. CHD-WM, integrated Chinese herbal decoction 
and western medicine; 95% CI, 95% confidence interval. Each point on the figure represents a relative risk (RR). The 
diamond represents the pooled estimate of effect, as calculated according to the random effects model. RR<1 means 
numerically lower response rate than WM, and RR>1 numerically higher response rate than WM. 95% CI doesn’t 
include the number 1 means statistical difference between the two groups. 
 
Pathological improvement 
 
Totally, 20 trials compared CHD (alone or integrated with WM) with WM in 1,959 patients reported pathological 
improvement. 154 (14.9%) of 1034 patients using CHD (alone or integrated with WM) failed to improve pathological 
change, compared with 360 (46.0%) of 925 patients using WM (RR=1.42; 95% CI 1.30-1.54), without significant 
heterogeneity between studies (I2=48%) (Figure 4). Evidence of publication bias was observed (Egger’s test p=0.002). 
In subgroup of CHD monotherapy versus WM, 13 studies reported pathological improvement rate. The result 
suggested that CHD had beneficial effect over WM (RR=1.33, 95% CI 1.22-1.45), without significant heterogeneity 
between studies (I2=36%). In subgroup of Int. CHD-WM versus WM, Int. CHD-WM was found to be beneficial over 
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WM (RR=1.57, 95% CI 1.37-1.80), without significant heterogeneity between studies (I2=11%). Statistically significant 
funnel plot asymmetry was only found in subgroup of CHD monotherapy versus WM (Egger’s test p=0.016), 
suggesting evidence of publication bias or other small study effects. 
 
 
Figure 4: Efficacy of CHD compared with WM in pathological improvement 
Note: CHD, Chinese herbal decoction; WM, western medicine; Int. CHD-WM, integrated Chinese herbal decoction 
and western medicine; 95% CI, 95% confidence interval. Each point on the figure represents a relative risk (RR). The 
diamond represents the pooled estimate of effect, as calculated according to the random effects model. RR<1 means 
numerically lower response rate than WM, and RR>1 numerically higher response rate than WM. 95% CI doesn’t 
include the number 1 means statistical difference between the two groupAdverse events 
Only minor side effects, such as urticarial, rash, and slight gastrointestinal discomfort, were found in CHD group 
(shown in Supplementary Table 2). There are no statistical differences in side effects between CHD (alone or with WM) 
and WM. 
 
Sensitivity analysis 
 
In order to evaluate the robustness of outcomes and identify sources of heterogeneity, we conducted prespecified 
sensitivity analyses. Totally 25 RCTs are at moderate risk of bias, 18 are at high risk of bias. In subgroup of CHD 
monotherapy the number is 15 (moderate) and six (high), while in subgroup of Int. CHD-WM the number is 10 
(moderate) and 11 (high) (see Supplementary Table 1). The results were similar in direction and magnitude to the 
primary results expect the eradication rate of H. pylori, suggesting the robustness of most results in this study. However 
heterogeneity between trials still existed in the some outcomes (Table 1).   
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Table 1: Sensitivity analyses of efficacy of CHM compared with WM in AG 
 Number of studies 
Number of 
subjects 
RR 95% CI I2 value 
Eradication rate of H. pylori 
CHM (alone or integrated 
with WM) versus WM 
5 544 1.16 [0.96, 1.41] 66% 
CHM versus WM 5 544 1.16 [0.96, 1.41] 66% 
Int. CHM-WM versus WM 0 0 N/A N/A N/A 
Clinical manifestations improvement 
CHM (alone or integrated 
with WM) versus WM 
20 2,213 1.27 [1.22, 1.33] 12% 
CHM versus WM 16 1,939 1.29 [1.23, 1.36] 10% 
Int. CHM-WM versus WM 4 274 1.18 [1.07, 1.31] 0% 
Pathological improvement 
CHM (alone or integrated 
with WM) versus WM 
12 1,284 1.44 [1.27, 1.63] 60% 
CHM versus WM 9 1,092 1.35 [1.20, 1.52] 53% 
Int. CHM-WM versus WM 3 192 1.87 [1.42, 2.45] 0% 
Note: N/A, not applicable; AG, atrophic gastritis; CHM, Chinese herbal medicine; WM, western medicine; Int. 
CHM-WM, integrated Chinese herbal medicine and western medicine; RR, relative risk; CI, confidence interval. 
 
Discussion 
 
Herbal decoction is a concentrated herbal tea in which raw roots, berries and barks are lightly simmered for hours 
to extract the useful constituents. Compared with Chinese herbal patent medicines, which is the ready-made pills or 
capsules of herbal extracts as products of modern pharmaceutical industry, CHD is considered to have more advantages 
such as flexibility in treatment and strictly following the basic TCM theory of Bianzheng Lunzhi strictly. Our study is 
the first systematic review and meta-analysis evaluating the efficacy and safety of all kinds of decoctions in the 
treatment of AG according to TCM symptom types. The results demonstrated that: 1) CHD may be more effective than 
WM in ameliorating clinical manifestations of AG; 2) CHD may be more effective than WM in reverting the 
precancerous lesions of AG; 3) CHD with WM may be more effective than WM in reverting the precancerous lesion of 
AG. Evidence from sensitivity analyses revealed that the primary results were relatively stable. However, similar 
conclusions cannot be drawn in the H. pylori eradication rate because of the significant heterogeneity between studies 
(I2＞50%) and low robustness confirmed by sensitivity analysis. The source of the significant heterogeneity was failed 
to be identified by sensitivity analysis and subgroup analysis.  
Our findings supported the clinical use of CHD for the alleviation of AG-related symptoms and pathologic change, 
which is consistent with the evidence from previous experimental studies. Pathologic changes and clinical symptoms of 
AG are mainly caused by H. pylori-related chronic inflammation in human gastric epithelial cells. Some herbs inhibits 
the generation of reactive oxygen species (ROS) prostaglandin E (2), cyclooxygenase-2 (COX-2), and interleukin 
(IL)-8 (Wang et al., 2012; Yu et al.,2013; Zaidi et al., 2012), and the strong anti-inflammatory activity can effectively 
protect gastric epithelial cells from gastric ulcer and cancer. Some herbs, such as Abrus cantoniensis Hance, have 
potent anti-H. pylori activity (Li et al.,2005; Safavi et al., 2015). However, the clinical efficacy of CHD to eradicate H. 
pylori in AG patients could not be concluded in the present study. We hypothesized the clinical and pathologic 
improvement of AG patients were more likely to be caused by the strong activity of CHD to inhibit H. pylori-related 
inflammation, than the eradication of H. pylori itself. Hence, we recommended that CHD be used as an adjunctive 
therapy to WM, but not used as an alternative to antibiotics for H. pylori eradication. 
We included various decoctions for treating different TCM symptom types related to AG, and used the modified 
Jadad scale with a new scoring item of Bianzheng Lunzhi. This study design made our research strictly follow the TCM 
therapeutic theory. The basic therapeutic theory of Bianzheng Lunzhi is fundamentally different from that of WM. In 
the Bianzheng Lunzhi theory, a TCM physician should take the body, mind and spirit into account to decide which 
symptom type (not a “disease”) each patient belongs to (Chen et al., 2003). Based on TCM syndrome differentiation, 
diseases should be further classified into different clinical types for therapy. Hence, different kinds of decoctions can be 
used, and dosage and/or formula in a certain decoction can be added or subtracted according to individual's symptom 
types and changing states of disease. The personalized therapy according to the symptom type differentiation is the 
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guarantee of its efficacy and should be integrated into clinical trial design (Flower et al., 2012). Unlike previous studies 
focusing on a certain herb or decoction, our study adequately considered this individual-based therapeutic features, and 
made an overall evaluation of all kinds of prescriptions such as Chai-Hu-Shu-Gan decoction, Shan-Jia-Yu-Wei 
decoction, Jian-Pi-Yi-Wei decoction, and Gan-Cao-Xie-Xin decoction for various TCM symptom types.  
Limitations of this review are as follows. Firstly, all the 42 articles that met the eligible criteria were at moderate 
to high risk of bias. Although sensitivity analyses excluding studies at high risk of bias found that the results were 
relatively stable, potential bias would exaggerate the efficacy to some extent (Kjaergard et al., 2001). Secondly, 
heterogeneity was observed in some results, especially the results of eradication rate of H. pylori. However, source of 
heterogeneity was failed to be identified by sensitivity analysis and subgroup analysis. Thirdly, publication bias, which 
might come from language bias, would potentially compromise the validity of some results and led to optimistic 
outcomes for treatment. Fourthly, our findings provided insufficient precision in the correlation between medical herbs 
and clinical outcomes. In fact, practitioners of Chinese medicine always prescribe mixtures of plants (decoction) 
instead of single plant as therapy. Therefore most RCTs regarding traditional Chinese medicine for atrophic gastritis is 
designed to evaluate the efficacy of decoctions. It is hard for us to evaluate the efficacy of certain plant for gastritis 
management using the meta-analysis. Last but not least, the herbs mentioned in all the included studies were not 
validated taxonomically. Although an overall analysis on efficacy of CHD for AG could be performed based on these 
studies, the inadequate taxonomical information limited the further species-level review on some specific herbs.  
 
Conclusions 
 
We recommended that CHD be prescribed as a complementary therapy to WM for atrophic gastritis, but its 
monotherapy for H. pylori eradication is not confirmed by existing clinical evidence. The evidence should be further 
strengthened because studies at low risk of bias were scarce. More large-scale, multicenter, prospective RCTs are 
needed therefore. We believe this article will stimulate further evaluation of CHD for AG therapy. 
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